carnitine

(redirected from Carnitine deficiency)
Also found in: Medical, Acronyms, Encyclopedia.
Related to Carnitine deficiency: L-carnitine

car·ni·tine

 (kär′nĭ-tēn′)
n.
A compound that functions in fatty acid metabolism by transporting fatty acids into mitochondria for energy production. It is naturally produced in the body and is present in many animal products, especially red meat. It is also sold as a dietary supplement for its purported health benefits.

[German Karnitin, from Karnin, a basic substance derived from meat, from Latin carō, carn-, flesh; see carnal.]
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.

carnitine

(ˈkɑːnɪˌtaɪn)
n
a white betaine, C7H15NO3, found in the liver and required for transporting fatty acids from the cytosol into the mitochondria
Collins English Dictionary – Complete and Unabridged, 12th Edition 2014 © HarperCollins Publishers 1991, 1994, 1998, 2000, 2003, 2006, 2007, 2009, 2011, 2014
Translations

carnitine

n carnitina
English-Spanish/Spanish-English Medical Dictionary Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved.
Mentioned in ?
References in periodicals archive ?
On the contrary, further supporting the role of carnitine on FA oxidation is the observation that healthy subjects and rats administered pivaloyl-conjugated antibiotics, known to induce severe systemic carnitine deficiency, demonstrate decreased heart rate and reduced rates of FA oxidation, decreased exercise capacity, and increased levels of ketone bodies in plasma [25, 26].
Dysfunction of OCTN2 leads to severe plasma and intracellular carnitine deficiency [1].
Despite the occurrence of secondary carnitine deficiency, the clinical significance of monitoring plasma carnitine concentrations and the role of supplementation is largely unknown.
Our hypothesis was that individuals with FMF would have lower FC levels than their healthy age and sex matched controls due to increased need of carnitine because of recurrent auto-inflammation; however, neither carnitine deficiency nor decreased FC levels compared to the healthy controls were detected in the study.
(7) Prolonged hepatic or renal compromise may also lead to carnitine deficiency. (4) Studies have shown that plasma levels of carnitine often do not reflect the tissue level of carnitine because of a significant intracellular-to-extracellular gradient, which is maintained by sodium-dependent pumps, thus maintaining a serum level higher than that in tissue.
We did not measure their plasma or muscle levels of carnitine, so we do not know whether these patients actually had a carnitine deficiency and/or how carnitine was retained in their muscles after supplementation.
Raskind and El-Chaar extensively reviewed the pathophysiology and significance of VPA-induced carnitine deficiency and recommended carnitine supplementation during VPA therapy.10-12 Some experimental and clinical data suggest that early intravenous supplementation with L-carnitine could improve survival in severe VPA-induced hepatotoxicity.13 The objective of this study was to observe the protective role of carnitine against the valproic acid induced hepatotoxicity in albino rats.
Hypertriglyceridemia associated with hyperglycinemia and carnitine deficiency has not been reported yet since it is rare to find.
Carnitine deficiency has been associated with congestive heart failure.
Clinical symptoms of carnitine deficiency include cachexia, glucose intolerance, anemia, heart arrhythmia, liver steatosis, growth retardation and skeletal muscles weakness [23-25].
Valproate-associated carnitine deficiency and malignant cerebral edema in the absence of hepatic failure.

Full browser ?